Edition:
India

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

3.53USD
21 Oct 2020
Change (% chg)

-- (--)
Prev Close
$3.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
157,587
52-wk High
$17.54
52-wk Low
$3.01

Latest Key Developments (Source: Significant Developments)

Evolus Provides Update On United States International Trade Commission (USITC) Case
Tuesday, 7 Jul 2020 

July 6 (Reuters) - Evolus Inc ::EVOLUS PROVIDES UPDATE ON UNITED STATES INTERNATIONAL TRADE COMMISSION (USITC) CASE.NON-BINDING INITIAL DECISION BY THE ALJ FINDS A VIOLATION OF SECTION 337 OF THE TARIFF ACT OF 1930.EVOLUS SAYS STRONGLY DISAGREE WITH INITIAL DETERMINATION AND LOOK FORWARD TO THE FULL COMMISSION’S FINAL DETERMINATION TARGETED FOR NOVEMBER 6, 2020.EVOLUS SAYS INTEND TO PETITION THE COMMISSION TO REVIEW THE INITIAL DETERMINATION.  Full Article

Evolus Expects 2019 Revenue To Be Back-loaded Towards Q4: Conf. Call
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Evolus Inc ::SAYS OF CONSUMER SWITCH FROM OTHER TOXINS TO JEUVEAU, APPROXIMATELY 70% CAME FROM BOTOX COSMETICS: CONF. CALL.SAYS EXPECTS 2019 REVENUE TO BE BACKLOADED TOWARDS THE FOURTH QUARTER.  Full Article

Evolus Posts Q2 Revenue Of $2.3 Million
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Evolus Inc ::EVOLUS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 REVENUE $2.3 MILLION.Q2 REVENUE ESTIMATE $450,000 -- REFINITIV IBES DATA.QTRLY NET LOSS PER SHARE $1.37.  Full Article

Alphaeon Corporation Sells 4 Million Shares In Evolus Inc
Thursday, 16 May 2019 

May 15 (Reuters) - Alphaeon Corporation::PRESS RELEASE - ALPHAEON CORPORATION SELLS 4 MILLION SHARES IN EVOLUS INC..  Full Article

Evolus Q1 Loss Per Share $0.40
Wednesday, 1 May 2019 

April 30 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.40.Q1 EARNINGS PER SHARE ESTIMATE $-0.79 -- REFINITIV IBES DATA.  Full Article

Evolus Provides Regulatory Update On Nuceiva In The European Union
Monday, 1 Apr 2019 

April 1 (Reuters) - Evolus Inc ::EVOLUS PROVIDES REGULATORY UPDATE ON NUCEIVA™ IN THE EUROPEAN UNION.EVOLUS - EXPECTS EMA TO ADOPT A FORMAL OPINION ON NUCEIVA MARKETING AUTHORIZATION APPLICATION (MAA) DURING APRIL 2019 COMMITTEE MEETING.  Full Article

Evolus Reports Q4 Loss Per Share $0.46
Tuesday, 19 Mar 2019 

March 18 (Reuters) - Evolus Inc ::EVOLUS REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.  Full Article

Evolus Secures $100 Million Senior Debt Facility With Oxford Finance Llc
Tuesday, 19 Mar 2019 

Evolus Inc ::EVOLUS SECURES $100 MILLION SENIOR DEBT FACILITY WITH OXFORD FINANCE LLC.EVOLUS INC - UNDER TERMS OF AGREEMENT, AN INITIAL TRANCHE OF $75 MILLION WAS FUNDED AT CLOSING.EVOLUS INC - REQUIRED TO MAKE INTEREST ONLY PAYMENTS ON A MONTHLY BASIS THROUGH APRIL 2022.EVOLUS INC - ENTIRE SENIOR DEBT FACILITY WILL MATURE ON MARCH 1, 2024.  Full Article

Evolus Receives FDA Approval For Jeuveau Prabotulinumtoxina-XVFS For Injection
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Evolus Inc ::EVOLUS RECEIVES FDA APPROVAL FOR JEUVEAU™ PRABOTULINUMTOXINA-XVFS FOR INJECTION.EVOLUS INC - JEUVEAU LAUNCH PLANNED IN SPRING 2019.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS THAT CAN BE LIFE THREATENING.EVOLUS INC - JEUVEAU MAY CAUSE SERIOUS SIDE EFFECTS SUCHS AS PROBLEMS SWALLOWING, SPEAKING, OR BREATHING AND SPREAD OF TOXIN EFFECTS.  Full Article

Evolus Receives Conditional FDA Acceptance Of Jeuveau Brand Name
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Evolus Inc ::EVOLUS RECEIVES CONDITIONAL FDA ACCEPTANCE OF JEUVEAU BRAND NAME.EVOLUS INC - IN COMING MONTHS, EVOLUS PLANS TO ACCELERATE ITS TRANSITION FROM AN RESEARCH AND DEVELOPMENT TO A COMMERCIAL STAGE COMPANY.  Full Article

BRIEF-Evolus Says Daewoong Pharmaceutical to invest $40 Million in Co

* EVOLUS STRENGTHENS BALANCE SHEET; SECURES $40 MILLION INVESTMENT